Viatris (VTRS) Receivables - Other (2019 - 2026)
Viatris' (VTRS) quarterly Receivables - Other came in at $499.0 million in Q1 2026, down 7.73% year-on-year from $540.8 million in Q1 2025, and up 9.98% quarter-over-quarter from $453.7 million in Q4 2025.
Viatris (VTRS) Receivables - Other (2019 - 2026) Analysis & Trends
Viatris' Receivables - Other history runs 8 years deep, the most recent figure standing at $499.0 million for Q1 2026.
- On a quarterly basis, Receivables - Other fell 7.73% year-over-year to $499.0 million in Q1 2026; TTM through Mar 2026 was $499.0 million, a 7.73% decrease from a year earlier, with the FY2025 full-year figure at $453.7 million, down 16.9% from the prior year.
- Receivables - Other grew to $499.0 million in Q1 2026 per VTRS's latest filing, from $453.7 million in the prior quarter.
- Across five years, Receivables - Other topped out at $882.5 million in Q2 2024 and bottomed at $453.7 million in Q4 2025.
- The 5-year median for Receivables - Other is $537.0 million (2022), against an average of $591.6 million.
- Across the five-year window, Receivables - Other surged 82.49% in 2024 and slumped 47.43% in 2025, its largest moves.
- Year by year, Receivables - Other stood at $570.7 million in 2022, then soared by 53.6% to $876.6 million in 2023, then sank by 37.71% to $546.0 million in 2024, then dropped by 16.9% to $453.7 million in 2025, then rose by 9.98% to $499.0 million in 2026.
- Per Business Quant, the three latest VTRS Receivables - Other figures stand at $499.0 million (Q1 2026), $453.7 million (Q4 2025), and $459.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 499.00 Mn |
| Mar 31, 2026 | 499.00 Mn |
| Dec 31, 2025 | 453.70 Mn |
| Dec 31, 2025 | 453.70 Mn |
| Sep 30, 2025 | 459.50 Mn |
| Sep 30, 2025 | 459.50 Mn |
| Jun 30, 2025 | 463.90 Mn |
| Jun 30, 2025 | 463.90 Mn |
| Mar 31, 2025 | 540.80 Mn |
| Mar 31, 2025 | 540.80 Mn |
| Dec 31, 2024 | 546.00 Mn |
| Dec 31, 2024 | 546.00 Mn |
| Sep 30, 2024 | 861.00 Mn |
| Sep 30, 2024 | 861.00 Mn |
| Jun 30, 2024 | 882.50 Mn |
| Jun 30, 2024 | 882.50 Mn |
| Mar 31, 2024 | 842.00 Mn |
| Mar 31, 2024 | 842.00 Mn |
| Dec 31, 2023 | 876.60 Mn |
| Dec 31, 2023 | 876.60 Mn |